Intensive Care admission sodium level in plasma > 142 mmol/L
Conditions
Interventions
Trade Name: Captopril / hydrochloorthiazide
Product Name: captopril / hydrochloorthiazide
Product Code: RVG25939
Pharmaceutical Form:
Pharmaceutical form of the placebo: Tablet
Route of administratio
Sponsors
Medical Center Leeuwarden
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: admission in the intensive care age > 18 years sodium level in plasma > 142 mmol/L Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30
Exclusion criteria
Exclusion criteria: sodium level > 142 mmol/L before admission no informed consent diabetes insipidus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To establish whether captopril / hydrochloorthiazide is able to reduce hypernatraemia in intensive care patients;Secondary Objective: To establish whether captopril / hydrochloorthiazide is able to reduce the timperiod of hypernatraemia in intensive care patients;Primary end point(s): 5 points decrease of sodium level in plasma in mmol/L;Timepoint(s) of evaluation of this end point: 7 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): decrease of duration of hypernatraemia;Timepoint(s) of evaluation of this end point: 7 days | — |
Countries
Netherlands
Contacts
Public Contactresearch coordinator Intensive Care
Medical Center Leeuwarden
Outcome results
None listed